Collagen material for face filling

By developing a combination of type 21 recombinant humanized collagen and auxiliary ingredients, the problem of insufficient stability and durability of existing collagen facial filler products has been solved, and more effective skin anti-aging and cosmetic effects have been achieved, especially for 21 The unique biological functions of collagen are optimized to provide a more comprehensive beauty solution.

CN118949130AActive Publication Date: 2024-11-15YANGTZE DELTA REGION INST OF TSINGHUA UNIV ZHEJIANG +1

Patent Information

Application Number
CN202411456995.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-18
Publication Date
2024-11-15
Estimated Expiration
2044-10-18

AI Technical Summary

Technical Problem

Existing collagen facial filler products are difficult to improve the stability and durability of collagen, and are difficult to optimize the biological functions of specific types of collagen, and are unable to effectively supplement and anti-aging.

Method used

Develop a type 21 recombinant humanized collagen to improve bioavailability by optimizing its amino acid sequence, and combine auxiliary components such as hyaluronic acid, antioxidants, etc. to form collagen materials for facial filling to promote skin moisture regulation, Improve skin structural integrity and elasticity.

Benefits of technology

It significantly improves the skin's moisture retention ability, reduces fine lines and wrinkles, enhances skin firmness and elasticity, provides a more lasting beauty effect, reduces the risk of immune response, and has multiple anti-aging effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118949130A_ABST
    Figure CN118949130A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological materials, in particular to a collagen material containing 21-type recombinant humanized collagen (ColpepA1 21) and application of the collagen material in face filling. The invention provides a collagen material for face filling by utilizing the characteristics that collagen not only provides an effective solution aiming at the skin aging phenomenon, but also promotes natural synthesis of collagen in the skin, optimizes the hydration state and the barrier function of the skin, enhances the self-repairing ability of the skin and the like. By means of local injection or external smearing, the smoothing and tightening effects of facial skin are rapidly achieved, and meanwhile the overall health condition of the skin can be improved after long-term use.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomaterials, and in particular relates to a collagen material and an application thereof in facial filling. Background Art

[0002] Collagen, as the most abundant protein in the human body, not only constitutes more than 30% of the total body protein, but is also a key element supporting the structure and function of various tissues in the human body. It is widely distributed in various connective tissues such as skin, bones, tendons, and blood vessels, building a three-dimensional network structure to provide the necessary mechanical strength and stability for the tissue. In terms of skin health, collagen plays a vital role in maintaining the firmness and elasticity of the skin, as well as keeping the skin surface smooth and shiny. However, with age, the natural production rate of collagen gradually slows down. In addition, the influence of ultraviolet radiation, environmental pollution and bad living habits leads to the gradual degradation and damage of existing collagen, and the skin begins to show signs of aging such as sagging, fine lines and wrinkles. This not only affects the appearance of the skin, but may also have a negative impact on bone density, tendon elasticity and vascular stability, thereby affecting the overall health status.

[0003] In facial filling products, the application of collagen is intended to directly supplement the collagen needed by the skin to fill the skin volume loss caused by collagen loss, restore the skin's firmness and elasticity, reduce wrinkles and fine lines, and thus achieve a rejuvenating effect. Taking advantage of its natural role in the skin structure and biocompatibility, collagen has become an ideal choice for facial filling and anti-aging treatment. However, current collagen facial filling products face challenges such as how to improve the stability of collagen, prolong its persistence in the skin, and how to enhance its permeability and bioavailability. In addition, the precise matching and supplementation of different types of collagen needs during the aging process is also a focus of further optimization and improvement of existing products. Current scientific research and product development are committed to solving these problems, through innovative technologies and formula improvements, to achieve more effective and lasting collagen supplementation and anti-aging effects.

[0004] In this context, it is particularly important to conduct in-depth research on specific types of collagen, such as type 21 collagen (COL21A1). Type 21 collagen is a non-fibrillar collagen that is relatively rare in the adult human body, accounting for less than 1% of the total collagen. Compared with other more well-known types of collagen, type 21 collagen has been relatively less studied. Type 21 collagen belongs to the small molecule collagen family. As part of the FACIT (fibril-associated collagen with interrupted triple helix) family, type 21 collagen plays a vital role in connecting extracellular matrix components. According to the research of Chou MY and Li HC, it may play a key role in the assembly of the extracellular matrix during angiogenesis [Chou MY, Li HC (March 2002)]. In addition, the gene expression of type 21 collagen is regulated by the developmental stage, and the expression level is higher in the fetal stage, suggesting that it may play an important role in the development of various tissues. Surendran et al.'s study revealed its functions in cardiac and aortic collagen formation and related to vascular remodeling and hypertension, further pointing out its potential value in promoting skin health and anti-aging [Surendran et al. (2016)]. This provides a new perspective for the study of COL21A1 in promoting skin health and anti-aging.

[0005] Although collagen materials on the market mainly rely on traditional collagen or its derivatives to replenish collagen loss in the skin, the effectiveness of these traditional products is often limited by the size of collagen molecules and the absorption rate of the skin, and they are difficult to optimize for the unique biological functions of specific types of collagen. However, based on the unique biological characteristics and mechanism of action of type 21 collagen, the facial filling products developed are expected to surpass traditional solutions and provide more targeted, highly bioavailable and multi-functional anti-aging therapies. These products can not only improve the appearance of the skin, but also promote overall health and slow the aging process through their effects on extracellular matrix composition and vascular health, representing an important direction for the future development of facial filling technology. Summary of the invention

[0006] The invention relates to a collagen material and application of the collagen material in facial filling.

[0007] In one aspect, the present invention provides a type 21 recombinant humanized collagen, wherein the amino acid sequence of the collagen is selected from SEQ ID No. 1: GKPGLQGPKGDPGLPGNPGYPGQPGQDGKPGYQGIAGTPGVPGSPGIQGARGLPGYKGEPGRDGDKGDRGLPGFPGLHGMPGSKGEMGAKGDKGSPGFYGKKGAKGEKGNAGFPGL PGPAGEPGRHGKDGLMGSPGFKGEAGSPGAPGQDGTRGEPGIPGFPGNRGLMGQKGEIGPPGQQGKKGAPGMPGLMGSNGSPGQPGTPGSKGSKGEPGIQGMPGASGLKGEPGATG This specific amino acid sequence of collagen is optimized to increase its bioavailability and potency in the skin.

[0008] In one embodiment, the collagen described in the present invention can enhance skin moisture regulation and optimize barrier function.

[0009] In one embodiment, the collagen of the present invention can promote the expression of the water channel protein AQP3, improve skin dryness and tightness by improving the skin's water retention capacity and reducing the water evaporation rate, and achieve the effect of promoting overall skin health and anti-aging.

[0010] In one embodiment, the collagen described in the present invention can reduce fine lines and wrinkles on the skin, increase skin firmness, and provide key support for anti-aging and skin rejuvenation.

[0011] In one embodiment, the collagen of the present invention can promote the production of type III collagen and significantly increase the content of type III collagen. The increased type III collagen content can enhance skin elasticity and repair ability, especially showing significant benefits in promoting wound healing and combating skin aging.

[0012] In one embodiment, the collagen of the present invention enhances the structural integrity of the skin and improves elasticity by promoting the production of type I collagen and type III collagen, thereby reducing signs of aging and promoting skin health.

[0013] In one embodiment, the collagen of the present invention demonstrates potential as an active ingredient in facial filler products in an in vitro skin model after UVA and UVB irradiation.

[0014] In one embodiment, the collagen of the present invention exhibits protective and repairing effects on skin damage.

[0015] In one embodiment, the collagen of the present invention helps to increase the thickness of the epidermal living cell layer.

[0016] In one embodiment, the collagen of the present invention helps to enhance the density of collagen fibers.

[0017] In one embodiment, the collagen of the present invention helps to increase the content of type I collagen.

[0018] In one embodiment, the collagen of the present invention helps to increase the content of type III collagen.

[0019] In one embodiment, the collagen of the present invention helps to increase the content of type IV collagen.

[0020] In one embodiment, the collagen of the present invention helps to increase the content of type XVII collagen.

[0021] Another aspect of the present invention provides a collagen material for facial filling, wherein the collagen material for facial filling comprises recombinant humanized collagen type 21 (ColpepA1 21), the amino acid sequence of the collagen is selected from SEQ ID No. 1, and further comprises one or more auxiliary ingredients selected from the following: a filling aid, a solvent, an antioxidant, an emulsifier, a moisturizer, a stabilizer, a pH adjuster, a thickener, etc.; Preferably, the filling aid comprises hyaluronic acid, calcium hydroxyapatite, polylactic acid, platelet-rich plasma, polymethyl methacrylate microspheres, liquid injectable silicone and the like.

[0022] In one embodiment, the collagen material of the present invention, wherein the concentration of the collagen is 0.0001% to 50% based on the total weight of the collagen material.

[0023] In one embodiment, the collagen material of the present invention, wherein the weight ratio of the collagen to the auxiliary components is selected from one or more of the following combinations: In one embodiment, the ratio of collagen to antibacterial agent is selected from 10:1 to 30:1; an appropriate concentration of antibacterial agent can effectively inhibit bacterial growth, but too high a concentration may cause skin irritation and allergic reactions.

[0024] In one embodiment, the ratio of collagen to anti-inflammatory agent is selected from 15:1 to 100:1; the facial filling process may cause mild inflammation, so the appropriate use of anti-inflammatory agents helps to alleviate these symptoms, but the dosage needs to be controlled to avoid inhibiting normal skin function.

[0025] In one embodiment, the ratio of collagen to growth factors is selected from 100:1 to 300:1; growth factors are very beneficial for promoting collagen synthesis and the natural recovery process of the skin, but should be used with caution in facial filling to avoid excessive growth or uneven skin texture.

[0026] In one embodiment, the ratio of collagen to moisturizer is selected from 1:1 to 8:1; moisturizers are particularly important in facial filling because they help maintain the smoothness and fullness of the skin. Increasing the ratio of moisturizer can effectively improve the durability and naturalness of the filling effect.

[0027] In one embodiment, the ratio of collagen to antioxidant is selected from 10:1 to 50:1; the antioxidant can prevent the preparation from oxidation, but its dosage should be controlled so as not to affect the long-term stability of the product.

[0028] In one embodiment, the ratio of collagen to emulsifier or thickener is selected from 5:1 to 20:1; it helps to improve the texture and stability of the product, but should be used in moderation to ensure the applicability and comfort of the final product.

[0029] Another aspect of the present invention provides a medical composition, wherein the composition comprises type 21 recombinant humanized collagen, and the amino acid sequence of the collagen is selected from SEQ ID No. 1 or any of the aforementioned collagen materials.

[0030] In one embodiment, the preparation form of the medical composition of the present invention includes but is not limited to the following forms: Injectable preparations, preferably, include but are not limited to injectable hydrogels, composite injections, etc., which are used to be directly injected into the skin through surgery to provide a deep facial filling effect.

[0031] Topical application preparations, preferably, include but are not limited to application gels, creams or lotions, suitable for daily skin care, assisting in reducing fine lines and restoring skin elasticity.

[0032] Solution preparations, preferably, include but are not limited to collagen solutions for microneedles or microneedle rollers, which promote the distribution and absorption of collagen in the skin in a minimally invasive manner.

[0033] In one embodiment, the product of the present invention may also be added with a pharmaceutically, food, health product or dietary acceptable carrier. For example, various compatible solid or liquid fillers, gel substances or solvents may be used. These carriers should be suitable for human use, have sufficient purity and low toxicity. Commonly used carriers include cellulose and its derivatives, polyols such as glycerol, and other pharmaceutical excipients such as talc, magnesium stearate, etc.

[0034] Another aspect of the present invention provides a use of type 21 recombinant humanized collagen in the preparation of a medical composition for facial filling, wherein the amino acid sequence of the collagen comprises the amino acid sequence shown in SEQ ID No.1.

[0035] Another aspect of the present invention provides a use of any one of the aforementioned collagen materials in the preparation of a medical composition for facial filling.

[0036] Another aspect of the present invention provides a method for preparing the collagen material for facial filling.

[0037] In one embodiment, the collagen material of the present invention is a collagen composite injection, wherein the raw materials used are 2%-10% (w / v) type 21 collagen and 0.1%-1% (w / v) hyaluronic acid; 0.05% (w / v) vitamin C is used as an antioxidant, and physiological saline is used as a solvent; the preparation process comprises the following steps: Dissolved antioxidants; Prepare collagen solution; Added hyaluronic acid; mixing an antioxidant solution; pH and viscosity adjustment; Sterile filtration and filling.

[0038] In one embodiment, the collagen material of the present invention is a collagen / hyaluronic acid blended injectable hydrogel; wherein the hydrogel structure is strengthened by using a crosslinking agent EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide), and the optimal formula is determined by adjusting the mixture of collagen and hyaluronic acid in different proportions and its reaction with different concentrations of EDC; the raw materials used are 1% - 5% (w / v) type 21 collagen and 0.5% - 2% (w / v) hyaluronic acid; the formula also includes phosphate buffer as a dissolution base, and 1% - 5% (w / v) glycerol is added as a moisturizer.

[0039] In one embodiment, the collagen material of the present invention is a collagen solution for microneedles / microneedle rollers, wherein the collagen solution is suitable for use in microneedles or microneedle rollers, and promotes the distribution and absorption of collagen in the skin in a minimally invasive manner. The concentration of collagen in the formula is relatively high, 3%-10% (w / v), to enhance its absorption through the microneedle channel. Excipients include hyaluronic acid 0.1% - 1% (w / v) to enhance moisturizing effects, urea 0.5% - 2% (w / v) as a penetration enhancer to help collagen penetrate the skin, and a buffer adjusted to a pH value close to that of the skin (pH 5.5 -7.0).

[0040] Advantages of the invention 1. Collagen type 21 can promote the production of type I and type III collagen, which are key components of skin elasticity and structure. This ability provides a new mechanism for collagen-based skin anti-aging strategies. By promoting the production of type I and type III collagen, type 21 collagen not only accelerates the wound healing process, but also improves the quality of the repaired skin. This is especially important for facial filling, because high-quality skin repair results can provide more natural and lasting cosmetic effects, reduce scar formation, and improve skin elasticity and structural stability. At the same time, type 21 collagen reduces fine lines and wrinkles and improves skin firmness and elasticity by increasing the production of type I and type III collagen. In the plastic surgery and beauty industry, this means providing a non-invasive skin rejuvenation solution, such as using microneedle rollers / microneedle treatments / topical products to deliver collagen to deeper layers of the skin / promote the production of type I and type III collagen without injections to achieve a filling effect.

[0041] 2. Since type 21 collagen exists naturally in the human body, its biocompatibility and low immunogenicity are particularly prominent when used as a facial filler material. This reduces the risk of immune response after injection and provides patients with a safer treatment option.

[0042] 3. In addition to being an effective facial filler, type 21 collagen also has a variety of potential added values ​​for promoting skin health, such as anti-aging and improving skin hydration. This allows it to be used not only as a filler, but also as an active ingredient in skin care and beauty products, providing a more comprehensive beauty solution. The type 21 recombinant humanized collagen (ColpepA1 21) described in the present invention shows significant advantages in skin anti-aging. While providing basic collagen supplementation, ColpepA1 21's unique efficacy and optimized molecular properties make it stand out among many collagen materials. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 The relative fluorescence intensity of type III collagen in cells of each experimental group is shown.

[0044] Figure 2 The bar graph shows the results of epidermal viable cell layer thickness, where ## indicates a significant difference compared with the blank control group (P<0.01), and ** indicates a significant difference compared with the negative control group (P<0.01). Figures 3 to 7 Same here.

[0045] Figure 3 A bar graph showing the relative area of ​​collagen fibers.

[0046] Figure 4A bar graph showing the relative integrated optical density (IOD) values ​​of Collagen I.

[0047] Figure 5 A bar graph showing relative integrated optical density (IOD) values ​​of Collagen III is shown.

[0048] Figure 6 A bar graph showing the relative integrated optical density (IOD) / Area values ​​of Collagen IV.

[0049] Figure 7 A bar graph showing the relative integrated optical density (IOD) / Area values ​​of Collagen XVII is shown.

[0050] Figure 8 The figure shows the effect of ColpepA1 21 compound injection on the cellular HYP content under oxidative stress.

[0051] Related definitions Unless otherwise specified, the following terms used in the specification and claims have the following meanings: As used herein, the term "collagen (COL)" refers to a vital structural protein in the human body, which is widely present in various tissues and organs, such as skin, bones, tendons, ligaments and cornea. The main function of these proteins is to provide strength, stability and elasticity to body tissues to ensure the normal functioning of various physiological functions. There are at least 28 known types of collagen, each of which plays a unique role and function in the body, forming a complex and finely regulated biological system.

[0052] As used herein, the term "collagen type 21 (COL21A1)" refers to a type of collagen present in the human body, which belongs to the family of small molecule collagens. As part of the FACIT (fibril-associated collagen with interrupted triple helix) family, collagen type 21 plays a vital role in connecting components of the extracellular matrix. This collagen, through its unique molecular structure, promotes interactions and links between different collagen types, thereby supporting the integrity and order of the extracellular matrix and its function in wound healing and tissue repair. Although it is not as well known as collagen types I and III, it plays a role in specific tissues and physiological processes, involving the composition of the extracellular matrix and the mechanism of skin repair. Although collagen type 21 is relatively rare in the adult human body, accounting for less than 1% of the total collagen, its possible role in cellular processes such as migration, proliferation and differentiation, as well as its potential role in maintaining the structure of the extracellular matrix and promoting tissue regeneration, are important directions for future research.

[0053] As used herein, the term "recombinant humanized collagen type 21 (ColpepA1 21)" refers to a protein expressed in Pichia pastoris through genetic recombination technology that simulates the type 21 collagen naturally present in the human body. The protein has similar biological functions and structural properties to natural type 21 collagen, and its amino acid sequence has a specific coding, which is intended to improve the health and anti-aging ability of the skin.

[0054] As used herein, the term “HaCaT (human keratinocytes)” refers to an immortalized human keratinocyte cell line that is widely used to study skin biology, skin pathology, and drug toxicity testing, and is considered a valuable research tool because of its ability to mimic the behavior of normal epidermal cells.

[0055] As used herein, the term "human foreskin fibroblasts HFF" refers to fibroblasts isolated from human fetal foreskin, which are an important component of the skin structure and are responsible for the synthesis of collagen and other extracellular matrix proteins. They are often used to study skin aging, wound healing and collagen synthesis.

[0056] As used herein, the term "human dermal fibroblasts (HDF)" refers to fibroblasts isolated from the human dermis. These cells play a central role in the formation of skin structure and are primarily responsible for the synthesis of collagen and other extracellular matrix proteins. HDF cells are commonly used in the study of skin aging, wound healing, disease models, and drug screening.

[0057] As used herein, the term "composition" refers to a preparation containing recombinant humanized collagen type 21 and possibly other auxiliary ingredients such as moisturizers, antioxidants or whitening ingredients, which work together to provide a more comprehensive skin care effect.

[0058] As used herein, the term "TGFβ1" (transforming growth factor β1) refers to a multifunctional cytokine that regulates cell proliferation, differentiation and migration. In skin physiology, TGFβ1 has an important influence on collagen synthesis, wound healing processes and anti-inflammatory effects.

[0059] As used herein, the term "HPR (phthalein oxalate)" is a synthetic retinol derivative commonly used in skin care products for its ability to promote cell renewal, enhance skin repair and improve the condition of skin aging.

[0060] As used herein, the term "ex vivo skin model" refers to a skin tissue sample extracted from a living body and maintained under laboratory conditions to simulate and study the biological properties of the skin in vitro and its response to various treatments.

[0061] As used herein, the terms "UVA and UVB radiation" refer to the two main types of ultraviolet radiation. UVA radiation (ultraviolet long wave) can penetrate deep into the dermis of the skin, causing long-term skin damage such as skin aging. UVB radiation (ultraviolet medium wave) mainly affects the epidermis of the skin and is the main cause of sunburn.

[0062] As used herein, the term "tissue morphology" refers to the microscopic structural state of the skin obtained by staining and microscopic observation, including the shape, size, arrangement and interaction of cells. Changes in tissue morphology, such as changes in epidermal thickness and dermal density, can intuitively reflect the skin's response to external factors, including damage from ultraviolet radiation, as well as the effectiveness of treatment and repair measures.

[0063] As used herein, the term "collagen fiber" refers to the fibrous structure of the dermis of the skin, which is mainly composed of type I and type III collagen. Collagen fibers provide the skin with the necessary elasticity and firmness and affect its overall appearance and touch. Changes in the content and quality of collagen fibers are key indicators for measuring the ability of facial filler products to strengthen the skin's support structure, improve skin sagging and reduce wrinkles.

[0064] As used herein, the term "collagen I" refers to the most abundant type of collagen in the human body, which is a fundamental building block of many tissues, including skin, bones, and tendons. Its primary function is to provide structural support and physical strength to these tissues, maintaining the elasticity and firmness of the skin. As we age, a decrease in the natural production of type I collagen is closely associated with sagging skin and wrinkle formation. In facial filler products, an increase in type I collagen is considered an important indicator of product effectiveness, especially in terms of anti-aging and improving skin structure.

[0065] As used herein, the term "collagen III" refers to the type of collagen that coexists with type I collagen in the skin structure, especially in young skin. It plays a vital role in maintaining skin elasticity and assisting in the healing process of damaged skin. After skin injury, a temporary increase in type III collagen helps repair and rebuild the skin's structure. Its decrease with age may affect the skin's elasticity and repair ability. The increase in type III collagen content in facial filler products shows the potential of the product to promote the skin's natural repair and enhance skin elasticity.

[0066] As used herein, the term "collagen IV" refers to the main component of the basement membrane, a specialized layer located between the epidermis and dermis that plays a key role in the skin's structural stability and barrier function. Type IV collagen forms the network structure of the basement membrane, providing a support layer for skin cells to maintain physical stability and promote the repair process. With age or external environmental damage, such as ultraviolet radiation, the function of the basement membrane may be impaired, resulting in skin aging. Therefore, an increase in the content of type IV collagen in facial filler products can help restore and protect the skin's basement membrane, helping to improve the overall health and appearance of the skin.

[0067] As used herein, the term "Collagen XVII" refers to a transmembrane collagen that is primarily localized on the epidermal basal cell membrane of the skin and participates in maintaining cell adhesion and the barrier function of the skin by interacting with other components in the basal membrane. It plays a vital role in maintaining skin integrity and responding to external stress. Damaged or aged skin may show a decrease in the expression of collagen type XVII, leading to weakened skin barrier function and sagging skin. Therefore, increasing the content of collagen type XVII in facial filler products can help strengthen the skin's self-repair ability and barrier function and reduce the damaging effects of external environmental factors on the skin.

[0068] As used herein, the term "composition" or "preparation" refers to a mixture containing one or more collagens described herein and other components, such as physiologically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of active ingredients, and thus exert biological activity.

[0069] As used herein, the term "antioxidant" refers to a class of substances that can neutralize free radicals and slow down or prevent cell damage, which is important for reducing oxidative stress caused by environmental factors and preventing skin aging.

[0070] As used herein, the term "emulsifier" refers to a substance that can help oil and water mix to form a stable emulsion, and is used in skin care products to improve the texture and stability of the product.

[0071] As used herein, the term "humectant" refers to a substance that attracts or locks in water, helping the skin retain moisture, and plays a vital role in maintaining the skin's hydration state and preventing dryness.

[0072] As used herein, the term "stabilizer" refers to a pharmaceutically acceptable excipient that protects the active pharmaceutical ingredient and / or formulation from chemical and / or physical degradation during manufacture, storage and use. Stabilizers include, but are not limited to, sugars, amino acids, salts, polyols and their metabolites as defined below, such as sodium chloride, calcium chloride, magnesium chloride, mannitol, sorbitol, sucrose, trehalose, arginine or its salts (such as arginine hydrochloride), glycine, alanine (α-alanine, β-alanine), betaine, leucine, lysine, glutamic acid, aspartic acid, proline, 4-hydroxyproline, sarcosine, γ-aminobutyric acid (GABA), opines, alanine, octopine, strombine) and trimethylamine N-oxide (TMAO), human serum albumin (hsa), bovine serum albumin (bsa), α-casein, globulin, α-lactalbumin, LDH, lysozyme, myoglobin, ovalbumin and RNaseA. Some stabilizers, such as sodium chloride, calcium chloride, magnesium chloride, mannitol, sorbitol, sucrose, etc., can also play a role in controlling osmotic pressure. The stabilizer specifically used in the present invention is selected from one or more of polyols, amino acids, salts, and sugars. Preferred salts are sodium chloride, preferred sugars are sucrose and trehalose, and preferred polyols are sorbitol and mannitol. Preferred amino acids are arginine or its salt (such as arginine hydrochloride), glycine, and proline. Preferred stabilizers are sodium chloride, mannitol, sorbitol, sucrose, trehalose, arginine hydrochloride, glycine, proline, sodium chloride-sorbitol, sodium chloride-mannitol, sodium chloride-sucrose, sodium chloride-trehalose, arginine hydrochloride-mannitol, and arginine hydrochloride-sucrose.

[0073] As used herein, the term "hydroxyproline (HYP)" refers to a non-essential amino acid that is primarily found in collagen and is an important component of the collagen tripeptide sequence. HYP plays a key role in the stable structure and tension resistance of collagen and is often used as a biomarker for evaluating collagen content and synthesis activity.

[0074] As used herein, the term "H2O2 oxidative stress treatment" refers to an experimental technique that uses hydrogen peroxide (H2O2) to treat cells, simulating the oxidative stress experienced by cells under physiological or pathological conditions. This treatment is often used to study the response mechanism of cells to oxidative damage, protective strategies, and the ability to survive under oxidative stress, especially in the study of anti-aging, antioxidant and disease models. DETAILED DESCRIPTION

[0075] In a specific embodiment, the materials and methods used are as follows: Cell lines: HaCaT (human keratinocytes) and HFF-1 (human fibroblasts) were purchased from Fenghui Biotechnology.

[0076] Reagents: CCK-8 kit (Japan Tongren CK04) was used for cell activity assessment, AQP3 (Shanghai ELISA) and type I collagen kit (Shanghai ELISA CMM2023H1) were used for related protein expression analysis.

[0077] Example 1: Production of Type III Collagen This example aims to evaluate the effect of recombinant humanized collagen type 21 (ColpepA1 21) on stimulating the production of type III collagen. Type III collagen is a key component to ensure the structural stability and elasticity of the skin, and is important for the rejuvenation and damage recovery of facial skin. Through this study, we aim to reveal the potential of ColpepA1 21 as an effective ingredient in facial filler and anti-aging collagen materials.

[0078] Experimental groups: Blank control group (Control): No treatment was performed to evaluate the expression level of type III collagen in cells without damage.

[0079] Negative control group: cells were treated with 5 J / cm² UVA to simulate the skin damage effect under sunlight.

[0080] Positive control group (HPR): 0.001% HPR (phthalein oxalate) was added after UVA damage, a therapeutic agent known to help skin repair.

[0081] ColpepA1 21 experimental group: 10 ppm and 50 ppm of type 21 recombinant humanized collagen were added after UVA damage.

[0082] HFF-1 fibroblasts were cultured separately and plated for 24 h. When the cell confluence was 70-80%, samples were treated with UVA induction and cultured for 24 h. Immunofluorescence (IF) detection method was used to quantitatively analyze the relative fluorescence intensity of type III collagen in the cells of each experimental group to detect the expression of type III collagen.

[0083] Data Collection and Analysis: Figure 1The relative fluorescence intensity results of type III collagen obtained by immunofluorescence technology are shown. As can be seen from the figure, the blank control group showed a normal level of type III collagen fluorescence intensity, which is the baseline expression level. The type III collagen fluorescence intensity of the UVA negative control group was significantly lower than that of the control group, indicating extracellular matrix damage caused by UVA irradiation. The 0.001% HPR positive control group increased relative to the UVA negative control group, but was still lower than the blank control group, indicating that HPR has a certain effect on extracellular matrix protection and repair. After adding 50 ppm ColpepA1 21 to the ColpepA1 21 experimental group, the fluorescence intensity of type III collagen increased significantly. Compared with the UVA negative control group, the promotion rate was 25.42%, indicating that ColpepA1 21 has a significant effect on promoting the production of type III collagen.

[0084] The effect of recombinant humanized collagen type 21 in promoting the production of type III collagen significantly improves the skin's ability to repair after damage and increases skin elasticity, which is very important in the anti-aging field. This effect not only supports the application of ColpepA1 21 in collagen materials for facial filling, but also emphasizes its significant potential in promoting skin repair after damage, improving skin elasticity and fighting aging. This provides valuable scientific basis for collagen materials for facial filling, demonstrates the unique value of ColpepA1 21 in improving skin health and delaying the aging process, and lays a solid foundation for the further development and commercial application of anti-aging collagen materials.

[0085] Example 2: In vitro skin model test This experiment aims to evaluate the effect of ColpepA1 21 on improving skin elasticity and reducing wrinkles, especially its role in skin repair and protection after UVA and UVB irradiation. By simulating UV exposure in daily environments, the application potential of ColpepA1 21 in facial filling products was evaluated. The experiment analyzed the changes in ex vivo skin tissue after UV irradiation, detected the changes in tissue morphology, collagen fibers, type I collagen, type III collagen, type IV collagen, and type XVII collagen content, evaluated its effects on skin structure and its anti-aging potential, and analyzed the application effect of type 21 collagen in facial filling.

[0086] Experimental groups: Blank control group: no treatment was performed.

[0087] Negative control group: The specific treatment is not specified, but it generally refers to a group that is not added with the test sample and is only subjected to the same external conditions.

[0088] Positive control group: treated with a mixture of VC (vitamin C) and VE (vitamin E) known to have firming and anti-wrinkle effects as an effect control.

[0089] Sample group (type 21 collagen group, ColpepA1 21): treated with type 21 recombinant humanized collagen (ColpepA1 21) at a concentration of 0.0125% (v / v) to test its firming and anti-wrinkle effects.

[0090] Main reagents: in vitro skin tissue culture medium (Guangdong Boxi Biological), PBS (Solaibao), vitamin C (VC, Sigma), vitamin E (VE, Sigma), anhydrous ethanol (Sinopharm), xylene (Sinopharm), hematoxylin (Biyuntian), eosin (Biyuntian), Collagen I antibody (Proteintech), Collagen III antibody (Abcam), Collagen IV antibody (Abcam), Collagen XVII antibody (Abcam), and paraformaldehyde (Biosharp).

[0091] Main equipment: CO2 incubator (Thermo, 1501), clean bench (Suzhou Antai, SW-CJ-1F), upright microscope (Olympus, BX53), UVA irradiator (Philips), UVB irradiator (Philips), fluorescence microscope (Leica, DM2500).

[0092] 1. Tissue Processing Immerse the freshly obtained skin tissue in 75% alcohol for 30 seconds to remove surface impurities and microorganisms. Wash three times with sterile PBS buffer to further clean and prepare the tissue. Cut the skin into 24±2 mm² tissue blocks, making sure the epidermis faces up and the dermis faces down, and place them in the culture mold. Place the culture mold in a 6-well plate, add 3.7 mL of culture medium to each well, and culture in an incubator at 37°C and 5% CO2, changing the culture medium every day.

[0093] 2. Irradiation and drug administration After 2 days of culture, the ex vivo skin tissue was irradiated and dosed according to the test group and its corresponding treatment conditions. The irradiation dose was set to UVA (30 J / cm²) and UVB (50 J / cm²), and the irradiation was continued for 4 days. Fresh culture medium was replaced after each irradiation, and the drug treatment was carried out. The positive control group used submerged drug administration; the sample group used surface drug administration. After 4 days of irradiation and drug administration, the ex vivo skin tissue was cultured for another 3 days, during which no irradiation was performed, and only sample drug administration was performed.

[0094] 3. Cleaning After the culture is completed, use sterile PBS solution to clean the residual reagent on the surface of the model, and use a sterile cotton swab to gently wipe off the residual liquid inside and outside the model.

[0095] 4. Tissue morphology and collagen fiber detection After washing, the skin tissue was fixed with 4% paraformaldehyde, embedded and sectioned, and stained with H&E and Masson, respectively. The images were photographed under a microscope and analyzed using Image-Pro® Plus image processing software.

[0096] 5. Immunofluorescence detection The model to be tested was fixed with 4% paraformaldehyde for 24 hours, and then immunofluorescence detection was performed. The model was photographed and observed under a microscope, and the images were collected and analyzed.

[0097] 6. Calculation of improvement rate According to the immunofluorescence results, the following formula was used to calculate the improvement rate of each indicator in each experimental group to further evaluate the effect of type 21 collagen.

[0098] Improvement rate (%) = (experimental group - blank control group) / blank control group × 100% 7. Statistical analysis of results GraphPad Prism software was used to draw graphs, and the results were expressed as mean ± standard deviation. The differences among the groups were compared by t-test statistical analysis.

[0099] Example 3-1: Tissue morphology test Tissue morphology reflects the microscopic structural state of the skin and is an important indicator for evaluating the health and aging of the skin. In the evaluation of facial filling products, by observing the changes in the thickness of the epidermis and the density of the dermis after treatment, we can intuitively understand the effectiveness of the product in resisting skin damage, promoting skin repair and improving skin firmness. When the skin is affected by external factors (such as UV radiation), its tissue structure will change, such as the thinning of the epidermis and the reduction of collagen fibers in the dermis, which are all manifestations of skin aging. Effective facial filling products should promote the proliferation of skin cells, restore or increase the thickness of the epidermis, and enhance the density and elasticity of the dermis, thereby improving the appearance and texture of the skin.

[0100] Figure 2The bar graph shows the results of epidermal living cell layer thickness, where ## indicates a significant difference compared with the blank control group (P<0.01), and ** indicates a significant difference compared with the negative control group (P<0.01). As shown in the figure, the blank control group (BC) shows the baseline level of epidermal living cell layer thickness without any treatment. After UV irradiation, the thickness of the epidermal living cell layer of the negative control group (NC) was significantly reduced, indicating that UV irradiation caused significant damage to the skin structure, resulting in thinning of the epidermis. After the positive control group (PC) was treated with known anti-aging ingredients (such as VC+VE), the epidermal thickness of the skin rebounded, proving that the positive control substance has a certain effect of resisting UV irradiation damage. Compared with the negative control group, the sample group (type 21 collagen ColpepA121, 0.0125%) showed a significant increase in the thickness of the epidermal living cell layer (the increase rate was 30.52%), indicating that ColpepA1 21 can significantly promote the increase of epidermal thickness and resist damage caused by UV irradiation.

[0101] The results showed that ColpepA1 21 provides an effective protection mechanism against damage from UV radiation and increases skin elasticity and firmness, which for facial filler products means it can effectively improve skin structure and restore or maintain the skin's youthful state, with potential therapeutic and cosmetic benefits.

[0102] Example 3-2: Collagen fiber test Collagen fibers are the main component of the dermis of the skin, mainly composed of type I and type III collagen, and have a decisive influence on the elasticity, firmness and overall appearance of the skin. In the evaluation of facial filler products, by measuring the content and quality of collagen fibers, the product's ability to enhance the skin's support structure, improve skin sagging and reduce wrinkles can be evaluated. With age or the influence of external factors such as ultraviolet rays, the collagen fibers in the skin will gradually decrease and be damaged, causing the skin to lose elasticity and firmness, and wrinkles and sagging will appear. Facial filler products can help restore the skin's elasticity and firmness and reduce wrinkles by stimulating the production of collagen.

[0103] Figure 3The relative area of ​​collagen fibers is shown in the bar graph. As shown in the figure, the blank control group (BC) was not treated, and the relative area of ​​collagen fibers can be regarded as a reference value of normal level. The relative area of ​​collagen fibers in the negative control group (NC) decreased significantly under UV irradiation, indicating that UV irradiation caused collagen fiber damage and skin structure degradation. The skin samples treated with substances known to have anti-aging effects in the positive control group (PC) recovered the relative area of ​​collagen fibers, indicating that the positive control substance can resist the damage of collagen fibers caused by UV irradiation. Compared with the negative control group, the relative area of ​​collagen fibers in the sample group (type 21 collagen ColpepA1 21, 0.0125%) increased significantly, with an increase rate of 43.48%. This means that ColpepA1 21 can significantly promote the increase of collagen fibers, improve the firmness and elasticity of the skin, and resist the phenomenon of aging.

[0104] The results showed that ColpepA1 21 as an active ingredient has significant skin tightening and anti-aging effects for facial filler products, as evidenced by the increase in collagen fiber content, making it a valuable ingredient.

[0105] Example 3-3: Type I collagen test Type I collagen is the most abundant type of collagen in human skin, accounting for about 80% of the total protein in the dermis of the skin. Its content is directly related to the structural integrity and function of the skin. As we age, the production of type I collagen decreases, and the skin becomes loose and wrinkled. Therefore, promoting the production of type I collagen is a key goal in the development of anti-aging and skin repair products. In the evaluation of facial filler products, the increase of type I collagen is regarded as an important indicator for improving skin structure and enhancing skin firmness and elasticity.

[0106] Figure 4The relative integrated optical density (IOD) value of Collagen I is shown in the bar graph. As shown in the figure, the blank control group (BC) was not treated in any way and showed the IOD value of Collagen I at the baseline, providing a benchmark for subsequent comparisons. After UV irradiation, the IOD value of Collagen I in the negative control group (NC) was significantly reduced, indicating that UV irradiation caused significant damage to Collagen I, resulting in a decrease in its content in the dermis. Compared with the negative control group, the IOD value of Collagen I in the positive control group (PC) was significantly increased, indicating that the VC+VE treatment in the positive control group helped to restore the content of Collagen I and counteract the damaging effect of UV. The sample group (type 21 collagen ColpepA1 21, 0.0125%) showed that the IOD value of Collagen I was similar to that of the positive control group, and was also significantly higher than that of the negative control group, with an increase rate of 159.38%. This indicates that type 21 collagen effectively promotes the increase of Collagen I, which is beneficial to strengthening the basic structure of the skin and improving the firmness and elasticity of the skin.

[0107] The results showed that ColpepA1 21 is an effective ingredient that can significantly enhance the content of Collagen I in the skin, which is very helpful for preventing and treating UV-induced skin damage, reducing the formation of wrinkles and improving skin firmness. This also provides a scientific basis for the application of ColpepA1 21 in facial filling products.

[0108] Example 3-4: Type III collagen (Collagen III) test Type III collagen is another important collagen in the skin. It is especially present in high levels in the skin of children and adolescents. Together with type I collagen, it forms the main support structure of the skin. It plays a vital role in the elasticity and repair process of the skin, especially during the healing process after skin injury, when the production of type III collagen will temporarily increase to help repair damaged skin structure. As we age, the proportion of type III collagen relative to type I collagen gradually decreases, affecting the elasticity and repair ability of the skin. The increase in type III collagen reflects the potential of the product in promoting skin repair and enhancing skin elasticity. For damaged or aging skin, products that can increase the content of type III collagen can help accelerate the skin's natural repair process and improve the overall texture and appearance of the skin. The increase in type III collagen is seen as a facial filler product with the ability to promote skin regeneration and restore the skin to a healthy state.

[0109] Figure 5The relative integrated optical density (IOD) value bar graph of Collagen III is shown. As shown in the figure, the blank control group (BC) presents a baseline level of Collagen III IOD value. After UV irradiation, the IOD value of type III collagen in the negative control group (NC) decreased significantly, indicating that UV irradiation significantly damaged type III collagen in the skin. Positive control group (PC): After known anti-aging treatment, the content of type III collagen increased significantly, indicating that the positive control treatment helps to restore the content of Collagen III after UV irradiation damage. The IOD value of type III collagen in the sample group (type 21 collagen ColpepA1 21, 0.0125%) was significantly higher than that in the negative control group, with an increase rate of 173.91%, indicating that type 21 collagen significantly promoted the production of type III collagen, improved skin elasticity and reduced the formation of wrinkles.

[0110] The results showed that ColpepA1 21 could be an effective ingredient in facial filler products, especially in promoting skin elasticity and anti-aging. The results highlighted its significant effect on increasing type III collagen content, which in turn showed that it could improve the texture and appearance of the skin, providing scientific evidence for the efficacy of facial filler products.

[0111] Example 3-5: Type IV collagen (Collagen IV) test Type IV collagen forms the network structure of the skin's basement membrane, providing a support layer to which the skin's surface cells can firmly attach. This structure not only maintains the skin's physical stability, but also plays a key role in the skin's repair process, the transport of nutrients, and the maintenance of its barrier function. With age or damage from the external environment (such as ultraviolet radiation), the destruction of type IV collagen can lead to impaired basement membrane function, thereby accelerating the skin's aging process. Therefore, the effect of facial fillers to increase the content of type IV collagen can help restore and protect the skin's basement membrane and improve the skin's overall health and appearance.

[0112] Figure 6The relative integrated optical density (IOD) / Area value bar graph of Collagen IV is shown. As shown in the figure, the blank control group (BC) represents the baseline level of Collagen IV in the untreated skin sample. Under the influence of UV irradiation, the content of Collagen IV in the negative control group (NC) decreased significantly, indicating that ultraviolet irradiation successfully induced skin aging conditions and caused damage to the basement membrane. Compared with the negative control group, the content of Collagen IV in the positive control group (PC) was significantly increased (marked as **), indicating that the treatment promoted the synthesis of Collagen IV or slowed down its degradation components, effectively counteracting the damage caused by UV irradiation. The content of Collagen IV in the sample group (type 21 collagen ColpepA1 21, 0.0125%) was also significantly higher than that in the negative control group, with an increase rate of 102.78%, indicating that ColpepA1 21 significantly promoted the synthesis or stability of Collagen IV and helped to restore the structure and function of the basement membrane.

[0113] The results showed that the application of ColpepA1 21 showed positive effects in improving skin health and preventing premature aging, which provides scientific basis for its use in facial fillers and skin care products. By enhancing the structural integrity and function of the basement membrane, ColpepA1 21 helps maintain the youthful state of the skin and is a valuable component in anti-aging strategies.

[0114] Example 3-6: Type XVII collagen (Collagen XVII) test Type XVII collagen is a transmembrane collagen located on the cell membrane of epidermal basal cells. It stabilizes cell attachment and assists in signaling between cells by interacting with other components in the basement membrane. This adhesion is essential for the integrity and barrier function of the skin. When the skin is damaged or aged, the expression of type XVII collagen may be affected, resulting in decreased adhesion of epidermal cells and weakened skin barrier function. Therefore, facial filler products that increase the content of type XVII collagen through external application can help strengthen the skin's barrier function and promote skin health. In the evaluation of facial filler products, the increase in type XVII collagen is believed to enhance the skin's self-repair ability, reduce the effects of damage caused by external environmental factors, and fight skin aging.

[0115] Figure 7The relative integrated optical density (IOD) / Area value bar graph of Collagen XVII is shown. As shown in the figure, the blank control group (BC) shows the normal content of Collagen XVII without any treatment, which serves as the benchmark of the experiment. The content of Collagen XVII in the negative control group (NC) was significantly reduced under UV irradiation, indicating that the UV irradiation conditions of the experiment led to a decrease in collagen content, simulating skin damage or aging. The positive control group (PC) was treated with known anti-aging agents, and the content of Collagen XVII was significantly increased. Compared with the negative control group, the sample group (type 21 collagen ColpepA1 21, 0.0125%) showed a significant increase in the content of Collagen XVII, with an increase rate of 50.94%, indicating that ColpepA1 21 effectively increased the content of Collagen XVII.

[0116] The results showed that type 21 collagen can effectively increase the content of Collagen XVII in the skin, enhance the skin's self-repair ability, and resist the influence of external environmental factors, thereby fighting aging. This provides scientific support for type 21 collagen as an effective facial anti-aging filling ingredient.

[0117] In summary, the positive effects of ColpepA1 21 not only emphasize its potential value in promoting skin repair, enhancing skin moisturizing, improving skin structural integrity and anti-photoaging, but also reveal its huge market potential as an effective ingredient for facial filling and anti-aging collagen materials. These experimental results provide a solid scientific basis for the application of ColpepA1 21 in facial filling collagen materials, and demonstrate its important role in improving skin appearance, promoting skin health and delaying aging.

[0118] Therefore, ColpepA1 21 can not only serve as a highly effective facial filler ingredient to promote the skin's natural repair and regeneration, but also play a key role in the development of future anti-aging products, providing innovative and effective solutions for consumers pursuing healthy, younger skin.

[0119] Example 4: Preparation of type 21 collagen ColpepA1 21 composite injection Material: Type 21 collagen: 2% (w / v) Physiological saline: Sufficient amount as solvent Hyaluronic acid: 1% (w / v) Vitamin C: 0.05% (w / v) as an antioxidant Preparation steps: Step 1: Dissolve the Antioxidant Dissolve vitamin C in a small amount of saline solution, making sure it is completely dissolved.

[0120] Step 2: Prepare collagen solution In a sterile container, slowly add the recombinant collagen powder to the remaining saline solution according to the desired final concentration. Stir slowly at room temperature using a magnetic stirrer until the collagen is completely dissolved.

[0121] Step 3: Add Hyaluronic Acid Add the pre-weighed amount of hyaluronic acid to the collagen solution and continue stirring to ensure uniform mixing until the hyaluronic acid is completely dissolved and a uniform viscous solution is formed.

[0122] Step 4: Mix the Antioxidant Solution Slowly add the dissolved vitamin C solution into the solution containing collagen and hyaluronic acid, and continue stirring until the entire solution is evenly mixed.

[0123] Step 5: pH and viscosity adjustment Check the pH value of the solution and adjust it to a pH range suitable for injection (approximately 7.0-7.4) if necessary. Adjust the viscosity of the solution to ensure that it is suitable for subcutaneous injection and has good fluidity but is not too thick.

[0124] Step 6: Sterile Filtration and Filling The solution was sterile filtered through a 0.22 micron sterile filter and the filtered solution was aseptically filled into pre-sterilized syringes.

[0125] Comparative Example 1: Preparation of Type III Collagen Composite Injection Material: Type III collagen: 2% (w / v) Physiological saline: Sufficient amount as solvent Hyaluronic acid: 1% (w / v) Vitamin C: 0.05% (w / v) as an antioxidant The preparation method is the same as Example 4.

[0126] Example 5: Effect of Type 21 Collagen Composite Injection on Human Collagen Synthesis This example aims to evaluate the ability of type 21 collagen compound injection to promote hydroxyproline (HYP) in human dermal fibroblasts (HDF). HYP is an important component of collagen and can reflect the content of total collagen. Therefore, by measuring the content of HYP, the application potential of the injection in the field of facial filling can be evaluated.

[0127] Experimental groups: Normal group (Control): No treatment was performed, representing the collagen expression level of cells in normal state.

[0128] H2O2 model group (NC): cells were treated with H2O2 to simulate oxidative damage caused by oxidative stress.

[0129] Sample group A: Based on the modeling group, damaged cells were treated with 0.5% ColpepA1 21.

[0130] Sample group B (positive control group): Based on the modeling group, an equal amount of 0.5% type III collagen type III collagen composite injection prepared by the method of comparative example 1 was used to treat damaged cells.

[0131] Sample group C: Based on the modeling group, an equal amount of 0.5% ColpepA1 21 type 21 collagen composite injection prepared by the method of Example 4 was used to treat damaged cells.

[0132] HDF cell anti-aging test: Cell seeding: dilute to 1×10 5 The cells were seeded at a density of 100 cells / ml and inoculated into 12-well plates at 1 ml / well of cell dilution. The plates were incubated in a cell culture incubator (37°C, 5% CO2, 95% RH) for 24±2 h. Three replicate wells were set up in each group according to the experimental groups.

[0133] Liquid preparation: Sample: Dissolve the sample with cell culture medium (add DMSO to dissolve the sample, but the final concentration of DMSO should not exceed 0.5%), and then dilute with cell culture medium; H2O2 working solution: Prepare H2O2 working solution by using serum-free culture medium to prepare H2O2 mother solution.

[0134] H2O2 induction: When the cell confluence in the 12-well plate reaches 50%-70%, remove the cell culture medium in each group, wash once with PBS, discard the solution, and add H2O2 working solution.

[0135] Sample addition: After induction, wash twice with PBS, add 1 ml of culture medium to each well of the normal group; add 1 ml of culture medium containing samples of corresponding concentrations to each well of the sample group. After sample addition, place the 12-well plate in an incubator (37°C, 5% CO2, 95% RH) and culture for 24±2 h.

[0136] HYP content detection: After 24±2 h of cell culture, the cells were collected and the OD value was read at 560 nm according to the instructions of the HYP detection kit.

[0137] Figure 8The data of HYP content in the normal group (Control), H2O2 modeling group (NC) and three sample groups are shown. The results showed that the HYP level in the normal group (Control) was the highest (22.71 ug / mL), which served as a baseline reference under normal physiological conditions. The HYP level in the H2O2 modeling group was significantly reduced to 6.98 ug / mL, indicating that H2O2 successfully simulated the reduction in collagen synthesis caused by oxidative stress. The HYP level (10.22 ug / mL) of sample group B (positive control group) using type III collagen composite injection was higher than that of the modeling group, showing a certain collagen recovery ability, but was still significantly lower than that of the control group. The HYP content of sample group A added with 0.5% ColpepA1 21 was further increased compared with that of sample group B, reaching 12.01 ug / mL; while the HYP level of sample group C added with type 21 collagen composite injection prepared by the method of Example 4 reached 18.57 ug / mL, which was significantly higher than that of other treatment groups and close to the level of the control group, showing the best collagen recovery ability.

[0138] The composite injection of ColpepA1 21 (sample group C) showed the best collagen-boosting effect, especially in the recovery after simulated oxidative damage. Its unique formula contains not only collagen, but also other ingredients such as hyaluronic acid and vitamin C that promote collagen synthesis or stability, which helps repair and protect the skin. The use of type 21 collagen composite injections, especially in facial filling and anti-aging treatments, has been shown to enhance the skin's collagen synthesis ability, which is of great value in improving the recovery of damaged skin and maintaining the elasticity and structural stability of the skin. These findings provide strong scientific support for its clinical application and provide an experimental basis for further development and optimization of anti-aging treatment strategies.

[0139] The specific embodiments of the present invention are described in detail above, but they are only examples, and the present invention is not limited to the specific embodiments described above. For those skilled in the art, any equivalent modifications and substitutions made to the present invention are also within the scope of the present invention. Therefore, the equalization changes and modifications made without departing from the spirit and scope of the present invention are all within the scope of the present invention.

Claims

1. A collagen material for facial filling, wherein: The collagen material comprises type 21 recombinant humanized collagen, the amino acid sequence of the collagen is selected from SEQ ID No. 1, and further comprises one or more auxiliary ingredients selected from the following: a filling aid, a solvent, an antioxidant, an emulsifier, a moisturizer, a stabilizer, a pH adjuster, and a thickener.

2. The collagen material according to claim 1, wherein Based on the total weight of the collagen material, the concentration of the collagen is 0.0001% to 50%.

3. The collagen material according to claim 1, wherein The weight ratio of the collagen and the auxiliary ingredients is selected from: Collagen and antimicrobial agent: 10:1~30:1; or Collagen and anti-inflammatory agent: 15:1~100:1; or Collagen and growth factor: 100:1~300:1; or Collagen and moisturizer: 1:1~8:1; or Collagen and antioxidants: 10:1~50:1; or Collagen and emulsifier or thickener: one or more combinations in the ratio of 5:1 to 20:

1.

4. A medical composition, wherein: The composition comprises the collagen material according to any one of claims 1-3.

5. The composition according to claim 4, wherein The preparation form of the composition includes one or more of an injection preparation, a topical application preparation, and a solution preparation.

6. The composition according to claim 5, wherein The injectable preparation is selected from one or more of injectable hydrogels and composite injectables.

7. The composition according to claim 6, wherein The injection preparation is a collagen compound injection.

8. The composition according to claim 5, wherein The topical smearable preparation is selected from one or more of a smearable gel, a cream or an emulsion.

9. The composition according to claim 5, wherein The solution preparation is selected from collagen solution for microneedles or microneedle rollers.

10. Use of a type 21 recombinant humanized collagen material in the preparation of a medical composition for facial filling, wherein: The amino acid sequence of the collagen material comprises the amino acid sequence shown in SEQ ID No.

1.

11. The use according to claim 10, wherein: The collagen material contained in the medical composition further contains one or more auxiliary ingredients selected from the following: a filling aid, a solvent, an antioxidant, an emulsifier, a moisturizer, a stabilizer, a pH adjuster, and a thickener.

12. The use according to claim 11, wherein: Based on the total weight of the collagen material contained in the medical composition, the concentration of the collagen is 0.0001% to 50%.

13. The use according to claim 11, wherein: The weight ratio of collagen and auxiliary components in the collagen material contained in the medical composition is selected from: Collagen and antimicrobial agent: 10:1~30:1; or Collagen and anti-inflammatory agent: 15:1~100:1; or Collagen and growth factor: 100:1~300:1; or Collagen and moisturizer: 1:1~8:1; or Collagen and antioxidants: 10:1~50:1; or Collagen and emulsifier or thickener: one or more combinations in the ratio of 5:1 to 20:1.

Citation Information

Patent Citations

  • Recombinant human-source collagen mask and preparation method thereof

    CN105213295A

  • Skin care composition having anti-aging and repairing effects, and application and preparation method thereof

    CN110448494A

  • Recombinant collagen and medical hydrogel thereof

    CN111072769A

  • Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications

    CN112041434A

  • Topical formulations of recombinant collagens

    CN112469432A

Cited By

  • Recombinant humanized XXI type collagen as well as preparation method and application thereof

    CN120329419A

  • Method for improving stem cell stemness of mesenchymal stem cells, and compound and composition thereof

    CN121950692A

  • Methods for improving stemness of mesenchymal stem cells and compounds and compositions therefor

    CN121950692B

  • Collagen peptide, composition and use thereof

    WO2026082178A1